对比增强CT前肾功能检测:个性化风险分层路径与全部检测方法的成本比较分析
本研究通过多中心映射当前对比增强CT路径、开发风险分层路径并建模比较成本。单中心数据显示78%(347/447)患者可避免扫描前实验室检测,风险分层路径有94%概率节约成本,估计5年潜在节约69,620英镑(95%CI:-13,295至154,603英镑)。作者提出该路径可能提高效率,需多中心评估。
要点
- 78%(347/447)患者无对比剂后急性肾损伤危险因素,可避免扫描前实验室检测。
- 仅24%门诊CT患者会通过问卷识别出需扫描当日床旁肌酐检测的危险因素。
- 风险分层路径有94%概率节约成本,估计5年潜在节约69,620英镑(95%CI:-13,295至154,603英镑)。
诊断标准与关键数值
- 替代路径以扫描当日筛查问卷进行风险分层和床旁肌酐检测,取代估算肾小球滤过率(eGFR)预评估。
- 单中心数据显示78%(n=347/447)患者无对比剂后急性肾损伤(AKI)危险因素,可避免扫描前实验室检测。
- 仅24%接受CT的门诊患者会识别出危险因素,从而触发扫描当日床旁检测。
- 风险分层路径节约成本的94%概率,估计5年潜在节约69,620英镑(95%CI:-13,295至154,603英镑)。
- 实验室血清肌酐检测费用为5.29英镑,床旁等效检测为5.96英镑。
临床应用与阅片要点
- 作者提出替代路径可能提高当前CT路径效率,需多中心评估以证明其在更广泛NHS层面嵌入的影响。
局限性
- 数据来自单中心,提示78%(n=347/447)患者可避免扫描前实验室检测。
- 需多中心评估以证明嵌入新路径在更广泛NHS层面的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To map current contrast-enhanced computed tomography (CT) pathways, develop a risk-stratified pathway, and model associated costs and resource use.
MATERIALS AND METHODS: Phase 1 comprised multicentre mapping of current practice and development of an alternative pathway, replacing pre-assessment of estimated glomerular filtration rate (eGFR) with a scan-day screening questionnaire for risk stratification and point of care (PoC) creatinine. Phase 2 measured resource use and analysis of routinely collected data, used to populate a model comparing the costs of current and risk-stratified pathways in Phase 3.
RESULTS: Site variation across a range of processes within the clinical care pathway was identified. Data from a single centre suggested that 78% (n=347/447) could have avoided their pre-scan laboratory test as they did not have post-contrast acute kidney injury (AKI) risk factors. Only 24% of outpatients who underwent computed tomography (CT) would have identified risk factors, which would have prompted a scan-day PoC test. There was a 94% probability that the risk-stratified pathway was cost-saving, with an estimated 5-year potential cost saving of £69,620 (95% CI: -£13,295-£154,603). Although the cost of a laboratory serum creatinine test is cheaper than the PoC equivalent (£5.29 versus £5.96), the screening questionnaire ruled out the need for a large majority of the eGFR measurements specifically for the CT examination.
CONCLUSION: The present study proposes an alternative pathway, which has the potential to improve the efficiency of the current CT pathway. A multicentre appraisal is required to demonstrate the impact of embedding this new pathway on a wider NHS level, particularly in light of new diagnostic guidance (DG37) published by NICE.
引用
- Shinkins B, Harris M, Lewington A, et al. Kidney function testing prior to contrast-enhanced CT: a comparative cost analysis of a personalised risk-stratified pathway versus a test all approach. Clin Radiol. 2020. PMID: 33109348. doi:10.1016/j.crad.2020.09.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。